Abstract
In April 2011, abiraterone acetate (Zytiga; Centocor Ortho Biotech), in combination with prednisone, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
Jemal, A. et al. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277–300 (2010).
Attard, G., Belldegrun, A. S. & de Bono, J. S. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 96, 1241–1246 (2005).
Attard, G. & de Bono, J. S. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin. Cancer Res. 17, 3867–3875 (2011).
Potter, G. A. et al. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17, 20-lyase): potential agents for the treatment of prostatic cancer. J. Med. Chem. 38, 2463–2471 (1995).
US Food and Drug Administration. FDA labeling information — Zytiga. FDA website [online], (2011).
de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).
Efstathiou, E, & Logothetis, C. J. A new therapy paradigm for prostate cancer founded on clinical observations. Clin. Cancer Res. 16, 1100–1107 (2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Christopher J. Logothetis has received research support from Johnson & Johnson, Bristol-Myers Squibb and Medivation, and honoraria from Johnson & Johnson and Bristol-Myers Squibb.
Eleni Efstathiou has received research support from Johnson & Johnson, Bristol-Myers Squibb and Medivation, and honoraria from Johnson & Johnson and Bristol-Myers Squibb.
Rights and permissions
About this article
Cite this article
Logothetis, C., Efstathiou, E., Manuguid, F. et al. Abiraterone acetate. Nat Rev Drug Discov 10, 573–574 (2011). https://doi.org/10.1038/nrd3516
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd3516
This article is cited by
-
Preclinical models of prostate cancer — modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo
Nature Reviews Urology (2023)
-
Azoarene activation for Schmidt-type reaction and mechanistic insights
Nature Communications (2022)
-
Reagent-controlled regiodivergent ring expansions of steroids
Nature Communications (2018)
